Debt-to-equity of Revolution Medicines, Inc. from 30 Sep 2020 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Revolution Medicines, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2020 to 31 Dec 2025.
  • Revolution Medicines, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 31%, a 159% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Revolution Medicines, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 31% +19% +159% 31 Dec 2025
Q3 2025 23% +11% +93% 30 Sep 2025
Q2 2025 17% +4.7% +37% 30 Jun 2025
Q1 2025 13% -0.47% -3.5% 31 Mar 2025
Q4 2024 12% -2.2% -15% 31 Dec 2024
Q3 2024 12% -3.8% -24% 30 Sep 2024
Q2 2024 13% -3.9% -24% 30 Jun 2024
Q1 2024 13% -5.4% -29% 31 Mar 2024
Q4 2023 14% -8% -36% 31 Dec 2023
Q3 2023 16% -7.6% -33% 30 Sep 2023
Q2 2023 16% -5.3% -24% 30 Jun 2023
Q1 2023 19% +0.39% +2.1% 31 Mar 2023
Q4 2022 22% +6.7% +43% 31 Dec 2022
Q3 2022 23% +8.8% +60% 30 Sep 2022
Q2 2022 22% +6.6% +44% 30 Jun 2022
Q1 2022 18% +0.58% +3.3% 31 Mar 2022
Q4 2021 15% -4.5% -23% 31 Dec 2021
Q3 2021 15% -15% -50% 30 Sep 2021
Q2 2021 15% 30 Jun 2021
Q1 2021 18% 31 Mar 2021
Q4 2020 20% 31 Dec 2020
Q3 2020 29% 30 Sep 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.